Clinical Trial

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Study acronym: TPG
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
Trial Details
NCT Number NCT07502872
Lead Sponsor Brown University
Collaborators: Incyte Corporation, Genentech, Inc., Natera, Inc.
Conditions Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Lymphoma, Lymphoma, B-Cell
Enrollment 30 participants
Start Date 2026-05-01
Primary Completion 2029-12-01 (estimated)
Study Completion 2029-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-31